Study Shows MIGS Makes up Nearly Half of Glaucoma Surgical Device Revenue

Micro-invasive glaucoma surgery (MIGS) stents are quickly becoming the norm. A new study from Market Scope titled “2019 Glaucoma Surgical Device Market Report,” shows that MIGS stents account for almost half of all glaucoma surgical device revenue in 2019. This is an even more impressive feat for the devices considering the loss of revenue that occurred from the Cypass Micro-Stent being recalled nearly a year ago. Alcon pulled Cypass off the market after five-year data revealed a higher rate of cell loss compared to patients who had cataract surgery alone. However, the report said Cypass being pulled off the market did slow down the adoption of MIGS devices and opened the door for other surgical and laser treatments. There are four FDA-approved MIGS stents: the Glaukos’s iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. That number could grow as Santen Pharmaceutical’s PreserFlow MicroShunt is the next MIGS device in line for FDA approval, the report said. Earlier this year, Osaka, Japan-based Santen Pharmaceutical announced today that its U.S. subsidiary entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt solely in the U.S. market. Glaukos, known as the pioneer in MIGS, has been pretty busy in 2019. Earlier this month, the San Clemente, CA-based company announced it would acquire Avedro, a hybrid ophthalmic pharmaceutical and med...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news